Next generation lung cancer mice model for conquering cancer stem

• Project/Area Number: 15H04830
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Respiratory organ internal medicine
• Research Institution: Okayama University
• Principal Investigator: Kiura Katsuyuki 岡山大学, 大学病院, 教授 (10243502)
• Co-Investigator(Kenkyū-buntansha): 大橋 圭明 岡山大学, 大学病院, 講師 (60729193) ; 久保 寿夫 岡山大学, 大学病院, 助教 (90726928)
• Research Collaborator: Yoshida Tadashi ; Takata Minoru
• Project Period (FY): 2015-04-01 – 2019-03-31
• Project Status: Completed (Fiscal Year 2018)
• Budget Amount: ¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000); Fiscal Year 2018: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2017: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2016: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2015: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
• Keywords: 肺癌 / EGFR変異 / 癌幹細胞 / 遺伝子改変マウスモデル / 非小細胞癌 / 肺癌幹細胞 / 臨床呼吸器学 / 呼吸器の腫瘍 / EGFR肺癌 / 内科 / 非小細胞肺癌

Outline of Final Research Achievements

NSCLC harboring EGFR mutations represents one of the most critical subgroups of the cancer in clinical practice.EGFR tyrosine-kinase inhibitors (EGFR-TKIs) are highly effective, but drug-resistance inevitably develops in the tumors. Therefore to achieve deeper and longer remission, an　alternative treatment strategy is required for lung cancers harboring EGFR mutations.
Lung tumors from the transgenic mouse strains were transplanted subcutaneously into C57BL/6J. The tumors maintained EGFR-dependency, and thus the EGFR-TKI gefitinib inhibited tumor growth; however, similar to human lung cancers, the tumors acquired resistance in 60 days, following gefitinib administration. Secondary EGFR T790M mutation in the tumors developed.
These syngeneic lung-cancer mouse models harboring EGFR mutations are suitable for studying the drug-resistance mechanisms and the role of the tumor microenvironment.

Academic Significance and Societal Importance of the Research Achievements

EGFR遺伝子の変異は非喫煙者に発生する肺癌の原因として最も高頻度であり、EGFR阻害薬が有効である。しかしながら1年程度で耐性化し、根治には至らない。なぜ耐性化するかを基礎的に解明し、原因に沿った新規治療法の開発を目指すため、よりヒト肺癌に近似した肺癌マウスモデルの作製をおこなった。遺伝子改変マウスから肺癌を摘出し、他のマウスへ移植し、どのようにEGFR-TKIに対して耐性化して進展するかを評価したところヒト肺癌と近似した耐性機序を呈することが分かった。このマウスモデルをプラットフォームとして免疫療法など新規治療法の開発が期待される。

Research Products

• [Journal Article] Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol. (2019)
  • Author(s): Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K.
  • Journal Title: Clin Lung Cancer. Volume: 29 Issue: 2 Pages: 134-138
  • DOI: 10.1016/j.cllc.2018.10.008
  • Peer Reviewed
• [Journal Article] Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice. (2019)
  • Author(s): Hotta K, Ninomiya K, Ichihara E, Kiura K.
  • Journal Title: Int J Clin Oncol. Volume: 24 Issue: 1 Pages: 41-45
  • DOI: 10.1007/s10147-018-1344-x
  • Peer Reviewed
• [Journal Article] A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403. (2018)
  • Author(s): Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K.
  • Journal Title: Cancer Chemother Pharmacol. Volume: 82 Issue: 6 Pages: 1031-1038
  • DOI: 10.1007/s00280-018-3694-5
  • Peer Reviewed
• [Journal Article] Study Protocol: Phase-Ib Trial of Nivolumab Combined With Metformin for Refractory/Recurrent Solid Tumors. (2018)
  • Author(s): Kubo T, Ninomiya T, Hotta K, Kozuki T, Toyooka S, Okada H, Fujiwara T, Udono H, Kiura K.
  • Journal Title: Clin Lung Cancer. Volume: 19 Issue: 6 Pages: e861-e864
  • DOI: 10.1016/j.cllc.2018.07.010
  • Peer Reviewed
• [Journal Article] Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions (2018)
  • Author(s): Kato Yuka、Ninomiya Kiichiro、Ohashi Kadoaki、Tomida Shuta、Makimoto Go、Watanabe Hiromi、Kudo Kenichiro、Matsumoto Shingo、Umemura Shigeki、Goto Koichi、Ichihara Eiki、Ninomiya Takashi、Kubo Toshio、Sato Akiko、Hotta Katsuyuki、Tabata Masahiro、Toyooka Shinichi、Maeda Yoshinobu、Kiura Katsuyuki
  • Journal Title: Cancer Science Volume: 109 Issue: 10 Pages: 3149-3158
  • DOI: 10.1111/cas.13752
  • Peer Reviewed / Open Access
• [Journal Article] Osimertinib Depletes EGFR T790M in the Spinal Fluid of Patients with Carcinomatous Meningitis of Lung Adenocarcinoma Harboring De Novo EGFR T790M. (2018)
  • Author(s): Senoo S, Ohashi K, Nishii K, Hara N, Kano H, Ninomiya K, Maeda Y, Kiura K.
  • Journal Title: J Thorac Oncol. Volume: 13 Issue: 8 Pages: e140-e142
  • DOI: 10.1016/j.jtho.2018.03.016
  • Peer Reviewed
• [Journal Article] Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer (2018)
  • Author(s): Ichihara Eiki、Hotta Katsuyuki、Kubo Toshio、Higashionna Tsukasa、Ninomiya Kiichiro、Ohashi Kadoaki、Tabata Masahiro、Maeda Yoshinobu、Kiura Katsuyuki
  • Journal Title: Oncotarget Volume: 9 Issue: 50 Pages: 29525-29531
  • DOI: 10.18632/oncotarget.25705
  • Peer Reviewed / Open Access
• [Journal Article] Needle wash solution cultures following EBUS-TBNA with or without endobronchial intubation. (2018)
  • Author(s): Minami D, Takigawa N, Oki M, Saka H, Shibayama T, Kiura K.
  • Journal Title: Respir Investig. Volume: 56 Issue: 4 Pages: 356-360
  • DOI: 10.1016/j.resinv.2018.03.006
  • Peer Reviewed
• [Journal Article] Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset (2018)
  • Author(s): Kiura Katsuyuki、Imamura Fumio、Kagamu Hiroshi、Matsumoto Shingo、Hida Toyoaki、Nakagawa Kazuhiko、Satouchi Miyako、Okamoto Isamu、Takenoyama Mitsuhiro、Fujisaka Yasuhito、Kurata Takayasu、Ito Masayuki、Tokushige Kota、Hatano Ben、Nishio Makoto
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 48 Issue: 4 Pages: 367-375
  • DOI: 10.1093/jjco/hyy016
  • Peer Reviewed
• [Journal Article] Second primary cancer in survivors of locally advanced non-small cell lung cancer treated with concurrent chemoradiation followed by surgery (2018)
  • Author(s): Makimoto Go、Kubo Toshio、Oze Isao、Ohashi Kadoaki、Hotta Katsuyuki、Tabata Masahiro、Soh Junichi、Toyooka Shinichi、Katsui Kuniaki、Takigawa Nagio、Tanimoto Mitsune、Kiura Katsuyuki
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 48 Issue: 3 Pages: 287-290
  • DOI: 10.1093/jjco/hyy003
  • Peer Reviewed
• [Journal Article] MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib (2018)
  • Author(s): Ninomiya Kiichiro、Ohashi Kadoaki、Makimoto Go、Tomida Shuta、Higo Hisao、Kayatani Hiroe、Ninomiya Takashi、Kubo Toshio、Ichihara Eiki、Hotta Katsuyuki、Tabata Masahiro、Maeda Yoshinobu、Kiura Katsuyuki
  • Journal Title: Scientific Reports Volume: 8 Issue: 1 Pages: 1955-1955
  • DOI: 10.1038/s41598-018-20326-z
  • Peer Reviewed / Open Access
• [Journal Article] Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples (2018)
  • Author(s): Kiura Katsuyuki、Yoh Kiyotaka、Katakami Nobuyuki、Nogami Naoyuki、Kasahara Kazuo、Takahashi Toshiaki、Okamoto Isamu、Cantarini Mireille、Hodge Rachel、Uchida Hirohiko
  • Journal Title: Cancer Science Volume: 109 Issue: 4 Pages: 1177-1184
  • DOI: 10.1111/cas.13511
  • Peer Reviewed
• [Journal Article] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results (2018)
  • Author(s): Reck Martin、Garon Edward B.、Paz-Ares Luis、Ponce Santiago、Jaime Jesus Corral、Juan Oscar、Nadal Ernest、Kiura Katsuyuki、Widau Ryan C.、He Shuang、Dalal Rita、Lee Pablo、Nakagawa Kazuhiko
  • Journal Title: Clinical Lung Cancer Volume: 19 Issue: 3 Pages: 213-220.e4
  • DOI: 10.1016/j.cllc.2017.11.003
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer (2018)
  • Author(s): Hotta Katsuyuki、Aoe Keisuke、Kozuki Toshiyuki、Ohashi Kadoaki、Ninomiya Kiichiro、Ichihara Eiki、Kubo Toshio、Ninomiya Takashi、Chikamori Kenichi、Harada Daijiro、Nogami Naoyuki、Hirata Taizo、Hinotsu Shiro、Toyooka Shinichi、Kiura Katsuyuki
  • Journal Title: Journal of Thoracic Oncology Volume: 13 Issue: 2 Pages: 273-279
  • DOI: 10.1016/j.jtho.2017.10.032
  • Peer Reviewed
• [Journal Article] A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404. (2018)
  • Author(s): Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Kuyama S, Kudo K, Bessho A, Fukamatsu N, Fujimoto N, Aoe K, Shibayama T, Sugimoto K, Takigawa N, Hotta K, Kiura K.
  • Journal Title: Lung Cancer. Volume: 115 Pages: 103-108
  • DOI: 10.1016/j.lungcan.2017.11.025
  • Peer Reviewed
• [Journal Article] Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations. (2018)
  • Author(s): Tamura T, Kato Y, Ohashi K, Ninomiya K, Makimoto G, Gotoda H, Kubo T, Ichihara E, Tanaka T, Ichimura K, Maeda Y, Hotta K, Kiura K.
  • Journal Title: Biochem Biophys Res Commun. Volume: 495 Issue: 1 Pages: 360-367
  • DOI: 10.1016/j.bbrc.2017.10.175
  • Peer Reviewed
• [Journal Article] A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202 (2017)
  • Author(s): Kuyama Shoichi、Ochi Nobuaki、Bessho Akihiro、Hotta Katsuyuki、Ikeda Genyo、Kishino Daizo、Kubo Toshio、Harada Daijiro、Fujimoto Nobukazu、Nakanishi Masamoto、Umeno Takahiro、Okada Toshiaki、Chikamori Kenichi、Yamagishi Tomoko、Ohashi Kadoaki、Ichihara Eiki、Takigawa Nagio、Tanimoto Mitsune、Kiura Katsuyuki
  • Journal Title: Lung Cancer Volume: 112 Pages: 188-194
  • DOI: 10.1016/j.lungcan.2017.08.010
  • Peer Reviewed
• [Journal Article] Clinical characteristics of Japanese candidates for lung transplant for interstitial lung disease and risk factors for early death while on the waiting list (2017)
  • Author(s): Higo Hisao、Kurosaki Takeshi、Ichihara Eiki、Kubo Toshio、Miyoshi Kentaroh、Otani Shinji、Sugimoto Seiichiro、Yamane Masaomi、Miyahara Nobuaki、Kiura Katsuyuki、Miyoshi Shinichiro、Oto Takahiro
  • Journal Title: Respiratory Investigation Volume: 55 Issue: 4 Pages: 264-269
  • DOI: 10.1016/j.resinv.2017.03.002
  • Peer Reviewed
• [Journal Article] Ceritinib versus chemotherapy in patients with ALK -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial (2017)
  • Author(s): Shaw Alice T、Kim Tae Min、Crino Lucio、Gridelli Cesare、Kiura Katsuyuki、Liu Geoffrey、Novello Silvia、Bearz Alessandra、Gautschi Oliver、Mok Tony、Nishio Makoto、Scagliotti Giorgio、Spigel David R、Deudon Stephanie、Zheng Cheng、Pantano Serafino、Urban Patrick、Massacesi Cristian、et al.
  • Journal Title: The Lancet Oncology Volume: 18 Issue: 7 Pages: 874-886
  • DOI: 10.1016/s1470-2045(17)30339-x
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo. (2017)
  • Author(s): Kudo K, Ohashi K, Makimoto G, Higo H, Kato Y, Kayatani H, Kurata Y, Takami Y, Minami D, Ninomiya T, Kubo T, Ichihara E, Sato A, Hotta K, Yoshino T, Tanimoto M, Kiura K.
  • Journal Title: Mol Oncol Volume: Epub Issue: 6 Pages: 670-681
  • DOI: 10.1002/1878-0261.12063
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset (2017)
  • Author(s): Hida Toyoaki、Satouchi Miyako、Nakagawa Kazuhiko、Seto Takashi、Matsumoto Shingo、Kiura Katsuyuki、Nokihara Hiroshi、Murakami Haruyasu、Tokushige Kota、Hatano Ben、Nishio Makoto
  • Journal Title: Japanese Journal of Clinical Oncology Volume: 47 Issue: 7 Pages: 618-624
  • DOI: 10.1093/jjco/hyx045
  • Peer Reviewed
• [Journal Article] Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP (2017)
  • Author(s): Tamura Tomohide、Kiura Katsuyuki、Seto Takashi、Nakagawa Kazuhiko、Maemondo Makoto、Inoue Akira、Hida Toyoaki、Yoshioka Hiroshige、Harada Masao、Ohe Yuichiro、Nogami Naoyuki、Murakami Haruyasu、Kuriki Hiroshi、Shimada Tadashi、Tanaka Tomohiro、Takeuchi Kengo、Nishio Makoto
  • Journal Title: Journal of Clinical Oncology Volume: 35 Issue: 14 Pages: 1515-1521
  • DOI: 10.1200/jco.2016.70.5749
  • Peer Reviewed
• [Journal Article] Study about the Efficacy of Metformin to Immune Function in Cancer Patients. (2016)
  • Author(s): Watanabe M, Yamamoto H, Eikawa S, Shien K, Shien T, Soh J, Hotta K, Wada J, Hinotsu S, Fujiwara T, Kiura K, Doihara H, Miyoshi S, Udono H, Toyooka S.
  • Journal Title: Acta Med Okayama. Volume: 70 Pages: 327-30
  • NAID: 120005828926
  • Peer Reviewed
• [Journal Article] Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer. (2016)
  • Author(s): Ochi N, Isozaki H, Takeyama M, Singer JW, Yamane H, Honda Y, Kiura K, Takigawa N.
  • Journal Title: Exp Cell Res. Volume: 344 Issue: 2 Pages: 194-200
  • DOI: 10.1016/j.yexcr.2016.05.008
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience. (2016)
  • Author(s): Kudo K, Hotta K, Bessho A, Nogami N, Kozuki T, Kuyama S, Inoue K, Harita S, Okada T, Gemba K, Fujii M, Takigawa N, Oda N, Tanimoto M, Kiura K.
  • Journal Title: Cancer Chemother Pharmacol. Volume: 77 Issue: 5 Pages: 1005-9
  • DOI: 10.1007/s00280-015-2910-9
  • Peer Reviewed
• [Journal Article] Chemotherapy for lung cancer: still alive! (2015)
  • Author(s): Katsuyuki Kiura
  • Journal Title: Japanese Journal of Clinical Oncology Volume: ４５ Issue: 7 Pages: 609-610
  • DOI: 10.1093/jjco/hyv074
  • Peer Reviewed
• [Journal Article] Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. (2015)
  • Author(s): Kudo K, Hotta K, Ichihara E, Yoshioka H, Kunimasa K, Tsubouchi K, Iwasaku M, Kato Y, Oze I, Takigawa N, Tanimoto M, Kiura K.
  • Journal Title: Cancer Chemother Pharmacol. Volume: 76 Issue: 2 Pages: 251-256
  • DOI: 10.1007/s00280-015-2789-5
  • Peer Reviewed
• [Journal Article] TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells (2015)
  • Author(s): Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S
  • Journal Title: PLoS One Volume: 10 Issue: 6 Pages: e0129838-e0129838
  • DOI: 10.1371/journal.pone.0129838
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. (2015)
  • Author(s): Kato T, Yoshioka H, Okamoto I, Yokoyama A, Hida T, Seto T, Kiura K, Massey D, Seki Y, Yamamoto N.
  • Journal Title: Cancer Sci. Volume: 106 Issue: 9 Pages: 1202-1211
  • DOI: 10.1111/cas.12723
  • Peer Reviewed
• [Journal Article] Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol. (2015)
  • Author(s): Hotta K, Sasaki J, Saeki S, Takigawa N, Katsui K, Takayama K, Nogami N, Shioyama Y, Bessho A, Kishimoto J, Tanimoto M, Kiura K, Ichinose Y.
  • Journal Title: Clin Lung Cancer. Volume: 17 Issue: 1 Pages: 75-79
  • DOI: 10.1016/j.cllc.2015.08.004
  • Peer Reviewed
• [Presentation] The novel osimertinib resistant lung cancer mice model harboring EGFR mutations driven by the SP-C promoter (2018)
  • Author(s): Kadoaki Ohashi, Hisao Higo, Go Makimoto, Kenichiro Kudo, Kazuya Nishii, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
  • Organizer: AACR Annual Meeting 2018
  • Int'l Joint Research
• [Presentation] Novel Syngenic Lung Cancer Mouse Model Harboring EGFR Mutations (2018)
  • Author(s): Kazuya Nishii, Kadoaki Ohashi, Hisao Higo, Kenichiro Kudo, Go Makimoto, Hiroe Kayatani, Hiromi Watanabe, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
  • Organizer: The 6th JCA-AACR Special Joint Conference
  • Int'l Joint Research
• [Presentation] In vivo efficacy of triplet therapy with osimertinib, cetuximab and bevacizumab for lung cancer cells harboring EGFR T790M (2018)
  • Author(s): Kazuya Nishii, Kadoaki Ohashi, Go Makimoto, Hisao Higo, Kiichiro Ninomiya, Hiroe Kayatani, Takashi Ninomiya, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
  • Organizer: AACR Annual Meeting 2018
  • Int'l Joint Research
• [Presentation] Analysis of the Rapid Acquired Resistance of ALK-positive Lung Cancers to Alectinib: A Comprehensive Study Using Autopsied Specimens and Patient-derived Cell Lines (2018)
  • Author(s): Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, (Shuta Tomida), Hiroe Kayatani, Hisao Higo, Kiichiro Ninomiya, Hiromi Watanabe, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, (Sinichi Toyooka), Yoshinobu Maeda, Katsuyuki Kiura
  • Organizer: The 6th JCA-AACR Special Joint Conference
  • Int'l Joint Research
• [Presentation] EGFR変異陽性NSCLCに対するafatinib・bevacizumab併用療法の第I相試験：OLCSG1404 (2018)
  • Author(s): 青江 啓介、近森 研一、前田 忠士、亀井 治人、二宮 崇、野上 尚之、別所 昭宏、久山 彰一、藤本 伸一、杉本 啓介、瀧川 奈義夫、木浦 勝行
  • Organizer: 第58回日本呼吸器学会学術講演会
• [Presentation] Acquired resistance to the third-generation EGFR inhibitor ASP8273 is associated with MET or NRAS gene amplifications in preclinical models (2017)
  • Author(s): Kiichiro Ninomiya, Kadoaki Ohashi, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Go Makimoto, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura.
  • Organizer: AACR Annual Meeting 2017
  • Int'l Joint Research
• [Presentation] A comprehensive analysis of autopsied specimens and patient-derived cell lines in ALK-positive lung cancers with rapid acquired resistance to alectinib (2017)
  • Author(s): Go Makimoto, Kadoaki Ohashi, Kazuya Nishii, Shuta Tomida, Hiroe Kayatani, Tomoki Tamura, Hisao Higo, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Akiko Sato, Katsuyuki Hotta, Masahiro Tabata, Katsuyuki Kiura
  • Organizer: AACR Annual Meeting 2017
  • Int'l Joint Research
• [Presentation] Clinical Characteristics of Japanese Candidates for Lung Transplant Due to Interstitial Lung Disease and Risk Factors for Early Death While on the Waiting List (2017)
  • Author(s): Hisao Higo , Eiki Ichihara , Takeshi Kurosaki , Kentaroh Miyoshi , Toshio Kubo , Shinji Otani , Seiichiro Sugimoto , Masaomi Yamane , Nobuaki Miyahara , Katsuyuki Kiura , Takahiro Oto
  • Organizer: American Thoracic Society 2017 International Conference
  • Int'l Joint Research
• [Presentation] Abstract 250: Interleukin-6 as potential predictive marker for therapeutic effect of Gefitinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations (2016)
  • Author(s): Tomoki Tamura, Katsuyuki Hotta, Yuka Kato, Takehiro Tanaka, Kouichi Ichimura, Kadoaki Oohashi, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Mitsune Tanimoto, Katsuyuki Kiura
  • Organizer: AACR 2016
  • Place of Presentation: Ernest N. Morial Convention Center New Orleans, Louisiana
  • Year and Date: 2016-04-16
  • Int'l Joint Research
• [Presentation] Abstract 5198: Combination effect of anti-VEGFR-2 antibody with erlotinib on EGFR mutant non-small cell lung cancer (2016)
  • Author(s): Hiroe Kayatani, Kadoaki Ohashi, Takeshi Imao, Kenichiro Kudo, Yuka Kato, Takashi Ninomiya, Toshio Kubo, Akiko Sato, Ktsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
  • Organizer: AACR 2016
  • Place of Presentation: Ernest N. Morial Convention Center New Orleans, Louisiana
  • Year and Date: 2016-04-16
  • Int'l Joint Research
• [Presentation] Abstract 4675: Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal growth factor receptor mutation-positive non-small cell lung cancer (2016)
  • Author(s): Nobuaki Ochi, Hideko Isozaki, Masami Takeyama, Jack W. Singer, Hiromichi Yamane, Yoshihiro Honda, Katsuyuki Kiura, Nagio Takigawa
  • Organizer: AACR 2016
  • Place of Presentation: Ernest N. Morial Convention Center New Orleans, Louisiana
  • Year and Date: 2016-04-16
• [Presentation] Abstract 1889: AXL and EGFR signaling mediate resistance to Crizotinib in non-small cell lung cancer cells harboring the ROS1 fusion gene (2016)
  • Author(s): Yuka Kato, Kadoaki Ohashi, Eiki Ichihara, Shuuta Tomida, Hiroe Kayatani, Kenichiro Kudo, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Toshiyuki Kozuki, Katsuyuki Hotta, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
  • Organizer: AACR 2016
  • Place of Presentation: Ernest N. Morial Convention Center New Orleans, Louisiana
  • Year and Date: 2016-04-16
  • Int'l Joint Research
• [Presentation] Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M (2016)
  • Author(s): AKadoaki Ohashi, Kenichiro Kudo, Eiki Ichihara, Hiroe Kayatani, Hisao Higo, Yuka Kato, Yasuko Kurata, Daisuke Minami, Takashi Ninomiya, Toshio Kubo, Katsuyuki Hotta, Mitsune Tanimoto, Katsuyuki Kiura
  • Organizer: AACR 2016
  • Place of Presentation: Ernest N. Morial Convention Center New Orleans, Louisiana
  • Year and Date: 2016-04-16
  • Int'l Joint Research